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Abstract
Background: The physiological responses to hypoxaemia and cellular hypoxia are poorly understood, and inter-
individual differences in performance at altitude and outcome in critical illness remain unexplained. We propose a
model for exploring adaptation to hypoxia in the critically ill: the study of healthy humans, progressively exposed
to environmental hypobaric hypoxia (EHH). The aim of this study was to describe the spectrum of adaptive
responses in humans exposed to graded EHH and identify factors (physiological and genetic) associated with inter-
individual variation in these responses.
Methods
Design: Observational cohort study of progressive incremental exposure to EHH.
Setting: University human physiology laboratory in London, UK (75 m) and 7 field laboratories in Nepal at 1300 m,
3500 m, 4250 m, 5300 m, 6400 m, 7950 m and 8400 m.
Participants: 198 healthy volunteers and 24 investigators trekking to Everest Base Camp (EBC) (5300 m). A subgroup
of 14 investigators studied at altitudes up to 8400 m on Everest.
Main outcome measures: Exercise capacity, exercise efficiency and economy, brain and muscle Near Infrared Spec-
troscopy, plasma biomarkers (including markers of inflammation), allele frequencies of known or suspected hypoxia
responsive genes, spirometry, neurocognitive testing, retinal imaging, pupilometry. In nested subgroups: microcircu-
latory imaging, muscle biopsies with proteomic and transcriptomic tissue analysis, continuous cardiac output mea-
surement, arterial blood gas measurement, trans-cranial Doppler, gastrointestinal tonometry, thromboelastography
and ocular saccadometry.
Results: Of 198 healthy volunteers leaving Kathmandu, 190 reached EBC (5300 m). All 24 investigators reached
EBC. The completion rate for planned testing was more than 99% in the investigator group and more than 95% in
the trekkers. Unique measurements were safely performed at extreme altitude, including the highest (altitude) field
measurements of exercise capacity, cerebral blood flow velocity and microvascular blood flow at 7950 m and
arterial blood gas measurement at 8400 m.
Conclusions: This study demonstrates the feasibility and safety of conducting a large healthy volunteer cohort
study of human adaptation to hypoxia in this difficult environment. Systematic measurements of a large set of
variables were achieved in 222 subjects and at altitudes up to 8400 m. The resulting dataset is a unique resource
for the study of genotype:phenotype interactions in relation to hypoxic adaptation.
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Background
A fall in cellular oxygen use occurs in diverse disease
states: oxygen uptake may be reduced (pulmonary dis-
ease), its mass transport diminished (cardiac contractile
failure or anaemia), or its local delivery (microvascular
disease) or cellular use (cellular dysoxia) impaired. In
the critically ill patient many or all of these factors may
exist simultaneously [1]. The (patho)physiological
responses to hypoxaemia and cellular hypoxia are far
from understood, and inter-individual differences in per-
formance at altitude and outcome in critical illness
remain unexplained. This lack of understanding stems
partly from difficulties in dissecting the pathways of
hypoxic adaptation in pathophysiological states. In criti-
cal illness, patient demographics, presenting conditions,
co-morbidities and therapies vary greatly, and multiple
biological characteristics are disturbed. Defining the spe-
cific effects of hypoxia, a single component in a multi-
factorial disease state, is therefore difficult. Clarifying
whether a change in a measured variable is the cause of
the hypoxia, or a response to it, is harder still.
Currently available models of critical illness are recog-
nised to have substantial limitations [1-4]. We therefore
propose an alternative model for exploring adaptation to
hypoxia in the critically ill: the study of healthy humans,
progressively exposed to environmental hypobaric
hypoxia in a controlled manner, during an ascent to
high altitude [1,5].
Barometric pressure falls progressively with increasing
altitude whilst the fractional inspired concentration of
oxygen remains constant resulting in a fall in the
inspired partial pressure of oxygen (PIO2). At Everest
Base Camp (5300 metres), the ambient (atmospheric)
partial pressure of oxygen (PATO2) is approximately half
that at sea level, and on Everest’s summit (8848 m) it is
one third of the sea level value.
Previous field studies at high altitude have provided
data on human adaptation to hypoxia in small groups (n
= 12-36) of highly selected subjects [6-9]. Whilst larger
prospective studies have been conducted by groups such
as Medical Expeditions (MEDEX), ascent rates varied
between subjects and hypoxic exposure was not standar-
dized [10-12]. Studies in large groups with tightly con-
trolled ascent profiles (ie identical hypoxic exposure)
have not previously been conducted. Furthermore,
developments in molecular genetics, along with novel
technologies for physiological measurement, allow new
questions to be addressed and genotype:phenotype rela-
tionships to be explored [13]. This approach may pro-
vide useful data to inform our understanding of
adaptation in situations where hypoxaemia/cellular
hypoxia is a fundamental problem.
The aim of Caudwell Xtreme Everest (CXE) [14] was
to study, comprehensively and prospectively, a large
cohort of healthy humans exposed to progressive, sus-
tained environmental hypobaric hypoxia. The results
will be used to drive a translational research agenda,
with the aim of developing novel diagnostic and thera-
peutic interventions for patients. Core hypotheses are as
follows: (1) Mechanisms distinct from those related to
global oxygen transport will in part explain inter-indivi-
dual differences in adaptation (functional capacity, organ
specific adaptation, absence of altitude illness) at high
altitude, (2) genotype differences will explain a substan-
tial proportion of intra-individual variation in environ-
mentally induced phenotypes (gene-environment
interactions). Possible mechanisms underlying hypoth-
esis one include alterations in metabolic efficiency and
changes in microcirculatory function. Subsidiary aims
include exploring the interaction between hypoxia and
inflammation, identifying biomarkers associated with
beneficial and adverse hypoxic adaptation, and charac-
terising the physiological state of well-adapted indivi-
duals close to the limit of hypoxia tolerance above 7500
metres. This paper describes the design and conduct of
the CXE study. We report the pattern of hypoxic expo-
sure, characteristics of the subject groups, and reasons
for subject drop-outs. We also discuss the strengths and
limitations of the proposed model.
Methods
CXE study design, risk management plan and individual
protocols were approved by the University College Lon-
don Research Ethics Committee (in accordance with the
declaration of Helsinki). Verbal and written informed
consent was obtained from all subjects. The study took
place between January and June 2007. The study was
initiated, designed and conducted by the UCL Centre
for Altitude Space and Extreme Environment Medicine
(CASE). All funding was unrestricted. All authors read
and approved this manuscript.
Study Participants
Eligible adults (candidate subjects) were aged over 18
years (no upper age limit) - the females not being preg-
nant - and were required to pass two separate health-
screening stages. Candidate subjects with diabetes melli-
tus, significant cardiac or significant respiratory disease
were excluded. Diabetes mellitus was defined as a
requirement for control of blood glucose either by diet,
oral hypoglycaemics or insulin therapy. Significant
respiratory disease was defined as disease that could
deteriorate at altitude and render the subject at risk dur-
ing the trek to Everest Base Camp. For example well-
controlled, mild asthma was not an exclusion criterion;
severe chronic obstructive airways disease was. Signifi-
cant cardiac disease was defined as disease that could
deteriorate at altitude and render the subject at risk
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during the trek. For example ischaemic heart disease
with angina and symptomatic heart failure were
excluded; controlled hypertension was not. Doctors qua-
lified in mountain medicine and working for the com-
pany responsible for travel arrangements to Everest Base
Camp performed the initial screening. They reviewed
the medical screening forms that were completed by all
subjects and determined fitness for travel to altitude.
The CXE medical officer (an experienced expedition
doctor, DL) independently confirmed fitness to travel to
altitude, as well as fitness to participate in the research
studies. In cases where further medical information was
required, DL contacted the candidate subjects directly
and, where appropriate and with consent, their medical
practitioners.
Additional exclusion criteria for cardiopulmonary
exercise testing (CPET) were based on the American
Thoracic Society/American College of Chest Physicians
guidelines for clinical exercise testing [15]. All subjects
with an absolute or relative contraindication, as defined
by these guidelines, were excluded from this protocol.
In addition any individual diagnosed by the expedition
medical team with altitude illness was excluded from
CPET whilst symptoms were present and treated appro-
priately. Subjects’ resting physiological variables (oxygen
saturation, pulse, blood pressure and electrocardiogram)
were monitored prior to the commencement of exercise
testing by investigators. Specific altitude dependent
symptom and physiological criteria were used to trigger
referral to the expedition medical team for assessment
and consideration of exclusion from CPET testing at
that laboratory (Table 1).
Two groups of healthy volunteers were studied (figure
1). Group 1 (trekkers) were members of the public
recruited by word of mouth and via public advertisement.
Group 2 (investigators) were selected from the investi-
gator team. The investigator team comprised 60 doctors,
scientists, allied health professionals and medical stu-
dents. Candidate investigators applied to CASE and were
selected following interview (MG, KM). Criteria used to
select group 2 subjects from the investigator team were
previous event free exposure to high altitude (>4000 m)
and previous experience of living in a harsh environment.
Group 2 was divided into base-camp laboratory staff
(who remained at Everest Base Camp for the duration of
the expedition) and the climbing team. Criteria for parti-
cipation in the climbing team were previous extreme alti-
tude experience (event free ascents over 6500 m), general
mountaineering experience (subjectively assessed by the
expedition leader and climbing leader, MG and SD) and
a demonstrated ability to conduct medical research at
high altitude. An additional criterion for summit climbers
was a previous successful event-free ascent over 8000 m.
Setting
Baseline studies were performed at the investigators’
human physiology laboratory at UCL (75 meters above
sea level) between January 4th and February 26th 2007.
Field studies were completed between 31st March and
6th June 2007. Altitudes are expressed as meters above
sea-level (m). Field studies were performed at dedicated
laboratories set up by the investigator team at Kath-
mandu (1300 m), Namche Bazaar (3500 m), Pheriche
(4250 m), Everest Base Camp (5300 m), Western Cwm
(6400 m), South Col (7950 m) and the Balcony (8400
m). Laboratory altitudes, barometric pressures and
inspired partial pressures of oxygen are summarised in
table 2.
Table 1 Criteria for exclusion from exercise testing at field laboratories and for stopping tests
Exclusion Criteria for testing at field laboratories
• Resting blood pressure >200 mmHg Systolic, and or >110 mmHg Diastolic
• Acute systemic infection (discuss with medical officer)
• AMS requiring treatment with acetazolamide, dexamethasone or nifedipine
• Acute chest pain
• New Arrhythmias or ECG changes
• Resting Arterial Oxygen Saturations <90% at sea level; <85% Kathmandu, <80% Namche <75% Pheriche, <70% at Everest Base Camp
Criteria for stopping test
• Excessive rise in blood pressure:
○ >250 mmHg Systolic; >115 mmHg Diastolic
• Drop in systolic blood pressure of >10 mmHg from baseline, with other indications of ischaemia (see below)
• >2 mm ST depression or >1 mm ST elevation
• Onset of angina or angina-like symptoms
• Onset of new arrhythmia other than ventricular ectopics
• Nervous system symptoms - ataxia, dizziness or near syncope
• Subject requests termination of test
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Intervention
All subjects flew from London to Kathmandu (over-
night). They then flew to Lukla (2800 m) in the
Khumbu region and trekked to Everest Base Camp
(EBC, 5300 m) (see figure 2). All subjects were sequen-
tially tested at laboratories in Kathmandu, Namche
Bazaar, Pheriche and Everest Base Camp. The time
course and altitude ascent profiles for Group 1 and
Group 2 are summarised in figures 2 and 3. Expedition
day 1 was defined as the day of departure from Kath-
mandu. The ascent rate was chosen to minimise the
incidence of high altitude illness and therefore maximise
the number of subjects able to contribute data at the
highest laboratory [16].
Group 1 (trekkers) was divided into 13 smaller groups of
a maximum of 16 subjects. Two groups left the UK each
week for the duration of the expedition. All Group 1 sub-
jects followed an identical ascent profile arriving at EBC on
day 11 (figures 2 and 3). All Group 2 (Investigator) subjects
followed an identical ascent profile to EBC arriving on day
13. This differed from that of group 1 due to the logistical
demands of establishing research laboratories and addi-
tional testing: additional time was thus spent in Kath-
mandu, and at Namche Bazaar, 3450 m (figure 3). On rest
days during the ascent to EBC, excursions were strictly lim-
ited such that all subjects remained within 300 vertical
metres of the laboratory altitude at all times in order to
maintain an identical pattern of hypoxic exposure.
Figure 1 Subject Groups in the Caudwell Xtreme Everest Study.
Table 2 Laboratory altitude, mean barometric pressure, mean laboratory temperature and inspired partial pressure of
oxygen
Laboratory Approx Altitude
metres
Ambient
Temperature ˚C
Barometric Pressure
millibar
Barometric Pressure
mmHg
Barometric
Pressure Kpa
PiO2
mmHg
PiO2
Kpa
LONDON 75 24.1 (1) 1005 754 (10) 100.5 (1.3) 148.0 19.7
KATHMANDU 1300 26.1 (1.5) 867 650 (3) 86.7 (0.4) 126.2 16.8
NAMCHE 3500 19.6 (2.6) 670 505 (3) 67.3 (0.4) 95.4 12.7
PHERICHE 4250 13.1 (1.7) 615 461 (2) 61.5 (0.3) 86.7 11.6
EBC 5300 21.5 (5.6) 538 404 (3) 53.8 (0.3) 74.7 9.9
WCWM 6400 12.7 (3.9) 467 350 (0.9) 46.7 (0.1) 63.4 8.5
SOUTH COL 7950 15.0 (8.9) 389 292 (2.3) 38.9 (0.3) 51.3 6.8
BALCONY 8400 Not recorded 363 272 36.3 47.1 6.3
Altitudes taken from map values to nearest 50 m; Barometric pressures and temperature are mean (standard deviation) values recorded during laboratory testing in the
field; PiO2 = Inspired partial pressure of oxygen -calculated from barometric pressures.
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The laboratory staff, (n = 10), subsequently remained
at EBC for the duration of the expedition (68 days). For
these investigators, excursions were limited to within
500 vertical metres of the EBC altitude for the duration
of the expedition. The climbing team (n = 14) followed
an identical ascent profile until the completion of all
testing at Camp 2 (Western Cwm), including identical
acclimatisation outings (figure 2). The laboratory staff
were not exposed to supplemental oxygen for the dura-
tion of the expedition. Climbers were not exposed to
any supplemental oxygen until the completion of testing
at Camp 2. All climbers used supplemental oxygen at
flow rates of 2-4l/min for the summit climb above
Camp 3 (7100 m) and at 0.5 l/min whilst sleeping at
and above Camp 3. Testing was repeated at the end of
the expedition (immediately prior to departure) for all
group 2 subjects at EBC (days 66 to 71).
Group 1 subjects were consistently tested either on
the day after arrival at any given altitude, or on the fol-
lowing day (Day 1 subjects, or Day 2 subjects: figure 3).
For each subject the day of testing was kept constant to
control for the effects of continued adaptation at the
laboratory altitude. Furthermore, subjects were tested at
the same time of day at all laboratories to control for
diurnal variations in physiological responses. At Kath-
mandu, Namche and Everest Base Camp, group 2
Figure 2 Ascent profile, mean barometric pressure and mean PiO2 for Group 1 (Trekkers), Group 2: (Investigators: Climbers and Base
Camp Team). Legend: Laboratories where testing was performed are labeled, intermediate altitudes indicate overnight stops without testing.
Figure 3 Schedule of testing for Group 1 (Trekkers) and Group 2 (Investigators). Legend: Expedition day 1 was defined as the day of
departure from Kathmandu. UK: United Kingdom; K: Kathmandu 1300 m; N: Namche 3500 m; P: Pheriche 4250 m; E: Everest Base Camp 5300 m.
Shaded boxes: Testing days Unshaded boxes Group 1: arrival day at laboratory Unshaded boxes Group 2: arrival day at laboratory and/or
laboratory set up day.
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subjects spent the first day after arrival setting up the
lab; at Pheriche testing began on the first day after arri-
val. For group 2, testing was performed over 4 days at
Kathmandu, 3 days at Namche, 2 days at Pheriche and
5 days at Everest Base Camp (figure 3). For the investi-
gator group, the order of testing was kept constant for
the core studies.
To minimise the confounding effects of hypoxic adap-
tation prior to the study period, all subjects refrained
from any form of hypoxic training (hypoxic tents etc)
and did not travel above 3000 m for 3 months prior to
departure.
Subjects did not take prophylactic medication (eg
acetazolamide) to prevent Acute Mountain Sickness
(AMS). We developed and used a set of guidelines for
the treatment of common altitude illnesses (eg AMS)
and non-altitude conditions (eg acute upper respiratory
tract infection, acute gastroenteritis), such that all indivi-
duals were treated in a standardized manner. All use of
medications was recorded so that individuals receiving
medication can be identified and where appropriate will
be analyzed as a subgroup. For example, the use of acet-
azolamide in the treatment of AMS might have an effect
on some of the resting physiological variables and we
intend to undertake a subgroup analysis exploring this
question.
Measurements
Core studies (Groups 1 and 2)
All subjects from both groups were recruited into the 10
core studies unless exclusion criteria were present. The
core studies were:
1. Diary: a daily diary of physiological variables and
symptoms (see below).
2. Maximum Exercise Capacity: Incremental CPET
using a standardized ramp protocol and breath-by-
breath expired gas analysis was used (Metamax 3b, Cor-
tex, Leipzig, Germany). Continuous vastus lateralis near
infrared spectroscopy (NIRS) (InSpectraTM Tissue
Spectrometer Model 325; Hutchinson Technology Inc,
Hutchinson, MN, USA) [17] and continuous cerebral
NIRS (Invos, Somanetics, MI, USA) were recorded at
rest, throughout the incremental exercise protocol and
during recovery. The lactate (or anaerobic) threshold
was identified during incremental exercise testing as a
change in the gradient of the VCO2-VO2 relationship
(the V-slope method, [18]), typically accompanied by a
systematic rise in the ventilatory equivalent for oxygen
(VE/VO2) and in end tidal oxygen (PETO2) without a
concomitant decrease in end-tidal CO2 (PETCO2) or
increase in the ventilatory equivalent for CO2 (VE/
VCO2) (ventilatory equivalents method) [19]. This
method was successfully validated against direct arterial
lactate measurements in a subgroup of subjects at
altitude. The arterial lactate threshold was identified as
the inflection point in the lactate response to incremen-
tal exercise above which there is a transition from a
phase of no increase, or a small increase, to a phase of
rapidly accelerating increase in blood lactate concentra-
tion [20].
3. Metabolic Efficiency: Exercise efficiency and exer-
cise economy were evaluated using constant work rate
cycling CPET (Metamax 3b, Cortex, Leipzig, Germany).
Three steady state work rates below lactate threshold
were assessed. Exercise economy was defined as the
relationship between oxygen consumption and work
rate during exercise; for exercise efficiency we calculated
delta efficiency.
4. Neurocognitive: Test battery assessing cognition,
attention, fine motor skills and memory: Trailmaking
Test, Rey Test (auditory verbal learning), Letter Cancel-
lation Test, Word Finding, Stroop Test, Block Design
and Groove Peg Board test. A cohort of control subjects
were tested using the same protocol and timings at sea-
level in order to control for any learning effect in this
study.
5. Pupilometry: The velocity and latency of the pupil-
lary reflex response was assessed at each altitude using a
hand-held ForSite Digital Pupillometer (Neuroptics Inc,
Irvine, CA).
6. Retinal Photography: Assessing the distribution
and depth of retinal haemorrhages using high-resolution
digital photography: TopCon TRC NW200 (Tokyo,
Japan).
7. Spirometry: Assessing standard spirometric indices
including forced vital capacity, forced expiratory volume
in one second and maximal voluntary ventilation using
an ultrasonic flowmeter (New Diagnostic Designs, Easy-
One™, NDD Medical Technologies, MA, USA)
8. Systemic Oxygen Content: Serial haemoglobin
concentration (Hemocue AB, Hemocue, Sweden), hae-
matocrit (microcentrifugation of whole blood using the
Sigma 1-14 microcentrifuge, Sigma, Germany) and SpO2
(Nonin Onyx 9500, Nonin Medical Inc, Minnesota,
USA)
9. Plasma Biomarkers: Serial inflammatory, metabolic
and tissue injury plasma biomarkers and nitric oxide
metabolites.
10. Genes Associated with Hypoxia
The Diary Study
All subjects in both study groups completed a physiolo-
gical and symptom scoring diary for each day of the
expedition using validated symptom scores. The Lake
Louise symptom score [21], the Environmental Symp-
toms Questionnaire [22] and a novel headache score
were recorded daily. The physiological profile included
resting heart rate, blood pressure (BP), respiratory rate
and arterial oxygen saturations (right index finger),
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repeated (with the exception of BP) after a standardised
two minute step exercise challenge (CXE step test: 20
cm step, firm base, alternate feet sequentially, 1 step up
or down per second by electronic metronome). Data
collection for the diary study was completed shortly
after waking each morning, prior to any oral intake. All
subjects rested in a sitting position for a minimum of
five minutes prior to recording resting measurements
and subjects were blinded to their own measurements.
Additional Studies for Group 1 (Trekkers)
Subgroups of Group 1 were also included in smaller stu-
dies: muscle and cardiac magnetic resonance imaging
(MRI) and 31P magnetic resonance spectroscopy (n = 7)
[23], sleep at altitude (n = 15), smell (n = 59), hypoxic
pulmonary vasoconstriction (n = 11) and performance
of a functionally-closed oxygen delivery device (n = 6)
(carried out after completion of all other testing).
Additional Studies for Group 2 (Investigators)
In addition to the core studies, all investigators partici-
pated in a weight and body composition study. Addi-
tional studies including olfactory and taste perception
direct laryngoscopy, resting cerebral Doppler, ocular
saccadometry and sub-lingual microcirculatory imaging
[24] were performed on all Group 2 subjects. Subgroups
of Group 2 were subjects for smaller studies: muscle
biopsy (n = 19), gastric tonometry (n = 10), gastric emp-
tying and nutrition (n = 12), lactate threshold CPET (n
= 5), oxygen transport and arterial blood gas analysis (n
= 10) [25], structural and volumetric 1.5T MRI (n = 21),
functional cardiac and skeletal muscle nuclear magnetic
resonance [23] (n = 7) and electrocardiogram (n = 17).
Individuals for subgroup studies were selected on the
basis of their planned maximum altitude and based on
practical timetabling considerations.
Study Design and Analysis Plan
The sample size of Group 1 reflected a compromise
between the constraints imposed by the capacity of the
available laboratories and the better predictive ability of
a larger population to identify clinically relevant rela-
tionships between physiological variables and different
conditions of environmental hypobaric hypoxia.
A central aim was to investigate changes in exercise
efficiency and exercise economy in response to condi-
tions of environmental hypobaric hypoxia. A second
related aim was to explore the association between
genetic variants and differences in physiological variables
(eg exercise efficiency). A sample size of 198 gives a
power of 0.88 for rejecting insignificant changes in exer-
cise efficiency (based on mean delta efficiency of 25.8%
with a standard deviation of 1.5% [26]) and 0.98 for
rejecting insignificant single gene effects for an allele
frequency of 10% with an alpha level of 5%. It is impor-
tant to note that the number of subjects is of one order
of magnitude greater than previous studies of this kind,
with a consequent increase in statistical power.
Given the different ascent profiles and previous alti-
tude exposure of the investigators, data arising from the
two groups will be analysed separately and these ana-
lyses will broadly be performed in two stages. In the
first stage, standard tests and regression models such as
ANOVA and generalized linear models [27] will be
employed for fitting changes in each observed variable
as a function of relevant predictors. Three categories of
such predictors are identified: base-line (sea-level) values
for observed variables, covariation of other observed
variables in hypoxia (at altitude) and genetic markers
(presence or absence of specific alleles). Genetic markers
(candidate genes) will be derived from promising candi-
dates identified from transcriptomic and proteomic ana-
lyses of tissue samples obtained during this experiment
in combination with pilot data from previous studies by
our group and hypoxia responsive genes identified in
the literature [13]. The aim of this first stage is to pro-
vide robust statistical data summaries describing the
main trends in each variable during the ascent. Mea-
sures of predictive power obtained by cross-validation
are a key component in guiding the refinement of the
simple models used in this first phase.
In the second stage of the analysis we aim at enriching
the data with plasma biomarker measurements obtained
by laboratory analysis of samples collected during the
expedition. Along with the simple models used for univari-
ate analyses, these supplementary data represent the sec-
ond key component for constructing a biological
description of pathways responsible for hypoxia adaptation
using multivariate hierarchical regression models [28]. The
aim of this second stage of the analysis is to refine the
description of the observed variables and to explore their
relationships in light of the supplementary plasma biomar-
ker data. Estimated conditional probabilities of variations
in one variable as a function of the others measure the
relative strength of the statistical relations leading to iden-
tifying the hypoxia adaptation pathway.
The key result of these statistical analyses in relation
to the management of critical care patients is the ability
to convert these estimated probabilistic relationships
into early stage predictions of poor adaptation to
hypoxia in critically ill patients using physiological,
plasma and genetic biomarkers. These predictions can
effectively act as a principled decision support system
that may point to an opportunity to intervene with spe-
cific targeted therapies.
Statistical analyses will be performed mainly using
standard and custom-made Matlab scripts (Mathworks,
MA,USA) that will be made publicly available. SPSS
(Mac v16 and Windows v15 SPSSinc Chicago, USA) will
be used for preliminary analysis.
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The main measures of goodness of fit and predictive
power used will be p-values, posterior probabilities and
cross-validation predictive probabilities for the observa-
ble variables.
Results
Two hundred and eight volunteers applied to join the
expedition as trekkers of whom four withdrew prior to
baseline sea level testing for personal reasons. One
volunteer was advised not to trek after medical screen-
ing because of severe respiratory disease requiring noc-
turnal non-invasive ventilation. Two hundred and three
volunteers were tested at sea level and five of these
withdrew prior to departure (one because of a back
injury and four for personal reasons). In the light of
findings at baseline exercise testing, six subjects were
withdrawn from subsequent maximum CPET testing,
and three of these were also withdrawn from the steady
state CPET testing. Sixty-three applicants applied to join
the investigator group of whom 60 were selected and
able to participate. Twenty-four were selected to be
investigator subjects (investigators) at EBC of whom 14
met criteria to become part of the climbing team (sum-
mit team = 10). One hundred and ninety eight trekkers
(Group 1) and 24 investigators (Group 2) who had been
tested in the UK commenced the trek. The baseline
characteristics of the study groups are summarized in
Table 3.
Of 198 trekkers who left the UK, 190 (96%) reached
Everest Base Camp. Eight did not arrive at EBC, due to
acute mountain sickness in three subjects (1.5% of total)
and non-altitude specific medical conditions in five
(2.5% of total) (table 4). In the investigators group
(group 2), all 24 subjects reached Everest Base Camp
(table 5). Of the climbing team, all 14 subjects reached
camp 2. Eight of ten summit climbers successfully
reached the summit of Mount Everest. One member of
the climbing team developed High Altitude Cerebral
Oedema on arrival at Camp 3 (7100 metres, Day 56)
during the final ascent to the summit. He was immedi-
ately treated with oxygen and dexamethasone and since
it was after nightfall was stabilized overnight at Camp 3.
At dawn he descended with assistance to Camp 2 and
then EBC. He made a full recovery and did not subse-
quently ascend above EBC. One member of the climbing
team turned back during the summit attempt with no
altitude illness. One member of the laboratory staff was
evacuated prior to the completion of the expedition
from Pheriche (4250 metres, Day 54) with septic shock
secondary to a severe community acquired pneumonia.
The subject made a full recovery after treatment in
Kathmandu. Subsequent investigations on return to the
UK, revealed the subject had mild, previously undiag-
nosed bronchiectasis (table 5).
The numbers of subjects tested in each protocol at
each laboratory for group 1 and group 2 are summarized
Table 3 Baseline Characteristics of the CXE study population
Group 1
(Trekkers)
Group 2
(Investigators)
Group 2 Subgroup
(Climbers)
Group 2 subgroup
(Lab staff)
number (%) number (%) number (%) number (%)
Total 198 (100) 24 (100) 14 (100) 10 (100)
Male 125 (63) 18 (75) 12 (86) 6 (60)
Previous Altitude Exposure(>3500 m) 85 (43) 23 (96) 14 (100) 9 (90)
Previous Extreme Altitude Exposure (>5000 m) 37 (19) 21 (88) 14 (100) 7 (70)
Smoker 13 (7) 0 (0) 0 (0) 0 (0)
Race - white 191 (97) 22 (92) 12 (86) 10 (100)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age 44.7 (13.7)
(range: 18-73)
35.2 (9.3)
(range: 19-59)
36 (6.9)
(range: 22-47)
34 (12.2)
(range: 19-59)
Height cm 173 (9.2) 176 (7.0) 178.4 (5.9) 172.7 (2.2)
Weight kg 75.2 (13.6) 77.2 (12.4) 97.8 (0.9) 72.2 (9.5)
BMI 25.1 (3.2) 24.8 (2.9) 25.3 (3.3) 24.1 (2.2)
Hb g/dl 14.5 (1.2) 14 (0.9) 14.2 (0.7) 13.6 (0.9)
Hct 43.7 (2.6) 43.9 (3.4) 43.9 (2.1) 43.5 (3.2)
SpO2% 97.7 (1.6) 97.9 (1.0) 97.9 (1.1)
Oxygen content mls/l 196.3 (16.2) 190.1 (11.6) 193.9 (10.0) 184.7 (12)
VO2max mls 2862 (799) 3624 (599) 3785 (505) 3398 (671)
VO2max mls/kg 38.2 (8.5) 47.2 (7.6) 47.4 (8.6) 47.0 (6.5)
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in tables 6 and 7 respectively. Mean laboratory pressures
and laboratory temperatures are recorded in table 2.
Published manuscripts reporting data from CXE to
date are:
1) Microcirculatory changes at altitude in the inves-
tigator group (n = 24) [24]
2) Muscle NIRS responses at altitude in the investi-
gator group (n = 24) [17]
3) Arterial blood gases and oxygen content in the
investigator group (n = 10) [25]
4) Skeletal muscle energetics (P-MRS) in 7 trekkers
and 7 climbers [23].
Discussion
Statement of principal findings
We have demonstrated the feasibility of safely conduct-
ing a large (>200 subject) study at extreme altitude with
a consistent pattern of hypoxic exposure. The study was
designed to explore inter-individual variability in adapta-
tion to hypoxia rather than the determinants of altitude
related illness. To this end, the slow ascent rate was
planned to avoid a significant incidence of altitude
related illness. The effectiveness of this strategy was
reflected in the high rate of success in reaching Everest
Base Camp when compared with previous reports of
ascents in this area and to the low incidence of missed
tests [16]. Consequently the completion rate for planned
testing was more than 99% in the investigator group
and more than 95% in the trekkers overall. All equip-
ment was tested for reliability and validity in hypobaric
and environmental chambers (-25 degrees Celsius) and
most devices were tested in the field during three pilot
expeditions to the Alps (2006) and the Himalaya (2005,
2006) prior to the CXE expedition. The very low rate of
equipment failure was an additional factor in the high
rate of successfully completed tests. In particular, valida-
tion of the cardiopulmonary exercise testing equipment
was an important element of expedition preparation, as
breath-by-breath equipment had not previously been
validated at extreme altitude. As a result of this prepara-
tion, only one exercise test was not completed for tech-
nical reasons. The pilot expeditions also permitted
investigators to gain practical experience of the experi-
mental protocols in field conditions and modify them
where necessary.
Strengths and weaknesses of the study
Strengths of this study are the large number of subjects
(for a study in this environment), the matched ascent
Table 4 Group 1 (Trekkers) - Subjects arriving at each laboratory and reasons for absence from laboratory
Kathmandu
(1300 m)
Namche
(3500 m)
Pheriche
(4250 m)
Everest Base Camp
(5300 m)
No of Trekkers Arriving at Laboratory 198 197 195 190
Reason for Absence from Laboratory
- gender, age, expedition day
nil absent Respiratory Tract infection (1)
M, age 73, Day 1
Abcess (1)
M, age 49, Day 3
AMS (1)
F, age 55, Day 3
AMS (1)
F, Age 39, Day 10
Angina (1)
F, age 60, Day 7
Respiratory Tract Infection (1)
M, age 68, Day 7
Diarrhoea and Vomiting (1)
F, age 59, Day 10
Recurrent Cluster Headache (1)
M, age 62, Day 8
Notes: AMS = Acute Mountain Sickness; M = male; F = Female
Table 5 Group 2 (Investigators) – Number of subjects arriving at each laboratory and reasons for absence from the
laboratory
Kathmandu
(1300 m)
Namche
(3500 m)
Pheriche
(4250 m)
EBC
(5300 m)
WCwm
(6400 m)
SCol
(7950 m)
EBCend
(5300 m)
Subjects at laboratory 24 24 24 24 14 12 23
Reason for absence from
Laboratory – gender, age,
expedition day
nil nil nil nil nil HACE (1)
M,42, Day 56
AMS (1)
F,35, Day 33
Septic Shock (1)
M,59, Day 50
HACE = high altitude cerebral oedema; AMS = acute mountain sickness; M = male; F = Female
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profile, sea-level control data, and the high rate of test
completion. Large subject numbers provide the statisti-
cal power to discriminate between, and identify associa-
tions with, different patterns of adaptation as well as to
detect differences in phenotypic response by somatic
genotype (prospective gene-environment interaction
study). Matched subject ascent profiles and baseline
measurements at sea-level control for variability of
exposure to hypoxia and thereby permit valid inter-indi-
vidual comparison of responses to hypoxia (with sub-
jects as their own controls), maximizing the signal (true
physiological differences) to noise (variations in expo-
sure to environmental hypoxia) ratio. In the neurocogni-
tive study, where a learning effect was a significant risk,
we recruited a parallel control group who were studied
over the same time-scale as the altitude exposed sub-
jects, but remained at sea-level. Fifty seven percent of
the trekker cohort (Group 1) were altitude naïve. This
sub-group is therefore not confounded by self-selection
due to prior altitude tolerance.
Weaknesses of this study include potential bias result-
ing from the method of recruitment and selection of the
subjects (non-random sample). However, randomisation
to environmental hypoxia exposure was not considered
a feasible option for this type of study (opportunistic
observation of individuals with a desire to visit the study
environment). Several factors suggest that the trekker
group is not representative of a ‘normal’ population (eg
gender distribution; prevalence of previous altitude
exposure, exercise capacity). In order to explore this, we
will undertake subgroup analyses investigating the influ-
ence of these factors on our findings. In the investigator
group self-selection due to previous altitude exposure is
a likely source of bias. In particular, the summit team
climbers had all experienced an event-free ascent over
8000 m. Investigator and trekker groups will therefore
be analysed separately.
Uncertain validity of measurements at high altitude is
another potential weakness that was minimised by prior
testing and validation of measurement devices in cold
and hypobaric chamber facilities and in the field. Envir-
onmental factors such as ambient temperature, subject
dehydration and concurrent illnesses may also have con-
founded results. However laboratory temperature was
much less variable than ambient temperature: for exam-
ple, mean laboratory temperature at Everest Base Camp
was 21.5 ˚C and the minimum and maximum tempera-
tures recorded in laboratories during testing (including
the South Col) were 4.6˚C and 33˚C respectively (table
2). All subjects were encouraged to maintain good
hydration (guided by the production of good quantities
of pale urine) and plasma osmolality remained constant.
Table 6 Group 1 (trekkers) (n = 198) - Testing performed at each laboratory
Sea Level Kathmandu
(1300 m)
Namche
(3500 m)
Pheriche
(4250 m)
EBC
(5300 m)
Subjects at laboratory 198 198 197 195 190
CORE STUDIES
Daily diary 198 195 196 194 190
CPX Ramp (+NIRS) 190* 189 184 183 153
CPX ME 195** n/a 191 n/a 164
Spirometry 198 197 190 176 185
Venesection 198 198 195 194 181
Neurocognitive 198 160 (on return) 195 n/a 185
Pupillometry 198 n/a 191 n/a 186
Cranial measurements 198 n/a n/a n/a n/a
Retinal photography 183 n/a n/a n/a 183
Plasma biomarkers 198 198 195 194 181
ADDITIONAL STUDIES
Hypoxic Pulmonary Vasoconstriction 31 screened13 selected n/a 11 n/a 11
Smell and taste 59 n/a n/a n/a 59
Sleep n/a n/a n/a n/a 15
Oxygen Delivery Circuit n/a n/a n/a n/a 6
Cardiac MRI and 31P-MRS 7 n/a n/a n/a n/a
Skeletal Muscle MRI and 31P-MRS [23] 7 n/a n/a n/a n/a
Structural and Volumetric MRI Study 7 n/a n/a n/a n/a
* 6 subjects withdrawn from incremental CPET prior to departure and 2 because of poor baseline data quality
** 3 subjects withdrawn from efficiency CPET prior to departure
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A detailed reporting system for medical problems was
used to identify those subjects in whom intercurrent ill-
ness was a potential confounder. The similarity between
data derived from chamber (eg Operation Everest II
[29]) and field studies (eg AMREE [8,30]) implies that
hypoxia is the over-riding physiological stimulus in field
studies and argues against substantial confounding by
environmental factors.
The use of supplemental oxygen at and above 7100
metres is also a potential weakness of this study. Supple-
mental oxygen was used for safety reasons; deaths above
8000 metres occur twice as frequently in individuals
breathing ambient air than in those using supplemental
oxygen [31]. To minimise the effect of this on our
observations, all measurements were made after at least
20 minutes breathing ambient air at which time any
additional oxygen would have been “washed out” by the
high levels of ventilation that occur at such altitudes
[25]. However, intermittent exposure to low flow (0.5-2
litres) oxygen supplementation may have altered the tra-
jectory of adaptation in these subjects and we cannot
know whether our observations would have differed had
they been made in climbers who had never used supple-
mental oxygen. The effect of supplemental oxygen on
arterial oxygen saturations is dependent on oxygen flow
rate, delivery system and minute ventilation and varies
between individuals [32,33]. Importantly, this was not an
issue for the trekker cohort (n = 198) as subjects were
not exposed to supplemental oxygen prior to measure-
ments being made.
We avoided the use of interventions to test candidate
mechanisms and the descriptive nature of the data may
be considered a weakness of this study. However, the
variety of outputs from different measurement techni-
ques (e.g. genomics, proteomics, plasma biomarkers and
functional MRI) allows observation of consistent
Table 7 Group 2 (Investigators) (n = 24) - Testing performed at each Laboratory
Archway
(75 m)
Kathmandu
(1300 m)
Namche
(3500 m)
Pheriche
(4280 m)
EBC (I)
(5300 m)
EBC (II)
(5300 m)
Camp 2
(6400 m)
South Col
(7950 m)
Subjects at laboratory 24 24 24 24 24 23 14 12
CORE STUDIES
Daily diary 24 24 24 24 24 23 14 5
CPX Ramp (+muscle and brain NIRS) [17] 24 24 22 24 23 22 14 5
CPX ME 24 24 23 n/a 24 23 14 n/a
Spirometry 24 24 24 23 23 23 14 6
Venesection 24 24 24 24 24 23 14 n/a
Neurocognitive 21 21 (on return) 21 21 21 n/a 13 6
Pupillometry 24 24 24 20 24 23 14 0
Cranial measurement 24 n/a n/a n/a n/a n/a n/a n/a
Retinal Photography 24 n/a n/a n/a 24 23 n/a n/a
Plasma biomarkers 24 24 24 24 24 23 n/a n/a
ADDITIONAL STUDIES
Arterial Blood Gases [25] 10 n/a n/a n/a 9 n/a 9 n/a
Gastric Tonometry 10 n/a n/a n/a n/a 9 n/a n/a
Cardiac Output 10 n/a n/a n/a n/a 9 n/a n/a
Microcirculation [24] 24 n/a 24 n/a 24 23 14 4
Weight & Body comp 24 24 24 24 24 23 13 n/a
Muscle Biopsy 20 n/a n/a n/a n/a 18 n/a n/a
ECG 19 19 19 19 19 19 n/a n/a
Oxygen circuit n/a n/a n/a n/a n/a n/a 5 n/a
Smell and taste 24 n/a n/a n/a n/a 24 n/a n/a
Thromboelastography 17 n/a n/a 17 n/a 14 n/a n/a
Cerebral Doppler 24 24 24 24 24 24 13 5
Saccadometry 22 22 22 22 22 22 12 n/a
Cardiac MRI and 31P-MRS 2 n/a n/a n/a n/a n/a n/a n/a
Skeletal Muscle MRI and 31P-MRS 7 n/a n/a n/a n/a n/a n/a n/a
MR Brain structural and volumetric studies 15 n/a n/a n/a n/a n/a n/a n/a
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patterns of response that may be strongly suggestive of
particular mechanisms.
The generalisability/external validity of data from this
type of study with respect to pathophysiological condi-
tions in critical illness and other “hypoxic” conditions
rests on the validity of the underlying model, which
remains uncertain. Accepted approaches to the study of
hypoxic adaptation in critical illness have included cellu-
lar (in vitro and ex vivo) [34], animal (in vivo) [35] and
computer (in silico) models [36]. In vivo studies are
considered to provide the most valid models of human
critical illness because they utilise integrative mamma-
lian physiology. However, discordance between animal
and human studies has raised concerns about the limita-
tions of these models [37,38]. Specifically there is con-
cern that in vivo models, fail to match the complexity of
human physiology in the acutely ill patient [39]. This
led us to propose that the study of healthy humans, pro-
gressively exposed to environmental hypobaric hypoxia
in a controlled manner, during an ascent to high alti-
tude, may be a valid model for exploring adaptation to
hypoxia in the critically ill: [1,5].
Furthermore, there is supportive evidence in the form
of common genetic determinants of performance at alti-
tude and outcome in hypoxic critical illness [40,41]. The
I allele of the insertion/deletion Angiotensin Converting
Enzyme (ACE) polymorphism is over-represented in
climbers who have successfully ascended over 7000
metres (without supplemental oxygen) [41] and 8000
metres [42]. The same I allele is associated with
increases survival in the Adult Respiratory Distresss
Syndrome (ARDS), an archetypal hypoxic illness, in cri-
tically ill patients [40,43].
Strengths and weaknesses in relation to other studies
In comparison to previous field and laboratory studies of
adaptation to hypoxia in humans, our study is unique in
both scale and in the variety of measurements made in a
cohort of subjects with matched hypoxic exposure. Several
chamber experiments (Operation Everest 1, 2 and 3) have
studied small cohorts (n = 4-8) of subjects in considerable
detail, but the small sample sizes have prevented meaning-
ful exploration of inter-individual differences [29,44,45].
Previous comprehensive altitude studies have studied
smaller numbers of subjects with un-matched ascent pro-
files [6-8]. Our study provides a unique opportunity to
explore inter-individual differences.
We explored the possibility of conducting this study in
a hypobaric chamber, but chose a field study for the fol-
lowing reasons. Recruiting subjects for a three-week
chamber study (in comparison with a trek to EBC)
would have been considerably more difficult. In addition
this approach might have incurred significant additional
costs; our subjects were entirely self-funded (and
contributed towards the costs of the research) whereas
volunteers in chamber studies often expect remunera-
tion. Furthermore, the high cost of running a chamber
study (continuous medical and technical cover) and lim-
ited availability of long duration hypoxia facilities cap-
able of accommodating large cohorts contributed to this
decision.
Unanswered questions and future research
Further research arising from this study will follow two
themes. First, studies in patients to explore the validity
of the model by applying the findings of this study to
pathophysiological problems in clinical settings [46,47].
Second, collecting additional healthy volunteer data
from subjects exposed to hypoxia in further field studies
and chamber studies. Future studies using this model of
field study might answer additional questions by using
alternative or additional measurement techniques, or
trialing novel interventions. Studying highland residents
and comparing patterns of physiological response with
lowland visitors to altitude, and studying responses in
younger subjects, amongst whom data is very limited
would also be valuable.
Conclusions
This study demonstrates the feasibility and safety of
conducting a large healthy volunteer cohort study of
human adaptation to hypoxia in this difficult environ-
ment. Systematic measurements of a large set of vari-
ables were achieved with high fidelity in 222 subjects
and at altitudes of up to 5300 metres. Hypoxic exposure
was successfully standardized allowing interrogation of
inter-individual variability in hypoxic adaptation. The
resulting dataset is a unique resource for the study of
genotype:phenotype interactions in relation to hypoxic
adaptation which may improve our understanding of
responses to hypoxia in critical illness.
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